Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294826 · ClinicalTrials.gov registry record · Phase 1
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Swedish Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01294826: Completed Phase 1 study, sponsored by Swedish Medical Center.
NCT01294826 is a Phase 1 study that has completed, run by Swedish Medical Center. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01294826, a Phase 1 study, has completed, sponsored by Swedish Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
Interventions
- DRUG Cetuximab
- DRUG AUY922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT01294826 record still lists
NCT01294826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT01294826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01294826 about?
NCT01294826 is a clinical study titled "Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer". The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
What is the current status of trial NCT01294826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01294826?
The interventions under investigation include: Cetuximab (DRUG), AUY922 (DRUG).
Who is sponsoring clinical trial NCT01294826?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01294826's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia